Vaccine Maitri

Vaccine Maitri ("English:" Vaccine Friendship) is a humanitarian initiative undertaken by the Indian government to provide COVID-19 vaccines to countries around the world. Indian government had started providing vaccines since 20 January 2021. As of 9April 2021, India had delivered around 64.5 million doses of vaccines to 85 countries. Of these, 10.5 million doses were gifted to 45 countries by the Government of India. The remaining 54 million were supplied by the Serum Institute of India under its commercial and COVAX obligations.
While speaking at the UN General Assembly high-level panel on the human rights situation in Syria, India pledged help the United Nations to vaccinate Syria through the "Vaccine Maitri" policy, as Syria is facing a dire situation compounded by COVID-19, winterisation and food insecurity.
200,000 doses of COVID-19 vaccines were gifted by India to the UN peacekeepers on 27 March to be distributed to all peacekeeping missions.
Vaccines.
India has two approved COVID-19 vaccines: Covishield and Covaxin. The Government of India supplied both the vaccines to various countries across the globe.
Covishield.
On 1 January 2021, the Drug Controller General of India, approved the emergency or conditional use of Oxford–AstraZeneca COVID-19 vaccine (marketed as Covishield). Covishield is developed by the University of Oxford and its spin-out company, Vaccitech. It’s a viral vector vaccine based on replication-deficient Adenovirus that causes cold in Chimpanzees. It can be stored, transported and handled at normal refrigerated conditions (two-eight degrees Celsius/ 36-46 degrees Fahrenheit). It has a shelf-life of at least six months.
Covaxin.
On 2 January 2021, BBV152 (marketed as Covaxin), first Indian vaccine, developed by Bharat Biotech in association with the Indian Council of Medical Research and National Institute of Virology received approval from the Drug Controller General of India for its emergency or conditional usage. However, this approval was met with some concern as the vaccine had not then completed phase-3 trials. On 3March 2021, Bharat Biotech announced that interim results of covaxin showed the 81% efficacy. Trial was conducted on the 25,800 people in India.
Vaccine supply.
India kicked off international shipment of the vaccines on 20 January 2021, only four days after starting its own vaccination program. Bhutan and Maldives were the first countries to receive vaccines as a grant by India. This was quickly followed by shipments to Nepal, Bangladesh, Myanmar and Seychelles. By mid-March 2021, India was also supplying vaccines on a commercial basis to countries including Canada, the UK, and Saudi Arabia. 
The Serum Institute of India was selected as a key supplier of cost-effective COVID-19 vaccines to the COVAX initiative. Several million doses of AstraZeneca's COVID-19 vaccine AZD1222 were supplied by India to various countries through the COVAX initiative.
However, in late March 2021, Modi's government temporarily froze exports of the AstraZeneca vaccine, citing India's own COVID crisis and the domestic need for these vaccines. In May, when COVAX was already short 140 million doses, the Serum Institute announced that it expected to maintain its suspension of vaccine deliveries to COVAX through the end of 2021.
Vaccines exported.
As of 15 March 2021, India had donated over 8 million doses to 37 countries.
As of 29 March 2021, India had exported 58 million doses to more than 65 nations.